Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure

European Journal of Haematology
Patrizia TosiMichele Cavo

Abstract

Salvage therapy of patients with advanced, relapsed and refractory multiple myeloma (MM) is often limited by poor marrow reserve and multi-organ impairment. In particular, renal failure occurs in up to 50% of such patients, and this further limits the use of conventional chemotherapy. Thalidomide, both alone and in combination with dexamethasone, has been demonstrated to be useful in patients with advanced MM, as responses could be achieved in 30-60% of the cases. From May 2000 to November 2003, 20 consecutive MM patients (15 males, five females, median age 66.5 yr) with stage III relapsed/refractory MM and renal failure, defined as serum creatinine >130 mmol/L, gave their informed consent to be enrolled in a clinical trial aimed at evaluating the efficacy and the toxic effects of thalidomide. Three patients were undergoing chronic haemodialysis during the time of entry in the study. Eight patients have been treated with thalidomide as a single agent, at a starting dose of 100 mg/d, that was to be increased to 400 mg/d in case of good tolerance. Twelve patients have been treated with thalidomide at the maximum dose of 200 mg/d plus dexamethasone 40 mg/d for four consecutive days every 4 wk. A >50% decrease in serum or urine M c...Continue Reading

Associated Clinical Trials

References

Feb 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W M GregoryJ S Malpas
Aug 1, 1990·Archives of Internal Medicine·R AlexanianD Dixon
Feb 17, 1994·The New England Journal of Medicine·R Alexanian, M Dimopoulos
Jun 5, 1997·The New England Journal of Medicine·R Bataille, J L Harousseau
Nov 24, 1999·The New England Journal of Medicine·S SinghalB Barlogie
Feb 26, 2000·British Journal of Haematology·A KnellerI Ben-Bassat
Aug 28, 2001·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M A DimopoulosN Anagnostopoulos
Sep 21, 2001·British Journal of Haematology·A BadrosG Tricot
Oct 16, 2001·European Journal of Clinical Pharmacology·T ErikssonP Höglund
Apr 17, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S HoechtU Hoeller
Dec 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Donna WeberRaymond Alexanian
Jan 24, 2004·The Journal of Pharmacy and Pharmacology·T ErikssonG A Kaysen

❮ Previous
Next ❯

Citations

Oct 14, 2004·Springer Seminars in Immunopathology·Norbert-Claude Gorin
Mar 10, 2010·Medical Oncology·Tiffany Richards, Donna Weber
Jul 1, 2009·Nature Reviews. Nephrology·Vaibhav SahniZiauddin Ahmed
Feb 22, 2012·Nature Reviews. Nephrology·Colin A HutchisonUNKNOWN International Kidney and Monoclonal Gammopathy Research Group
Sep 19, 2006·European Journal of Haematology·M Teresa CibeiraJoan Bladé
Nov 3, 2011·Bone Marrow Research·Stephanie StringerPaul Cockwell
Jan 18, 2011·Hematology·Meletios A Dimopoulos, Evangelos Terpos
Feb 5, 2008·Blood·Antonio PalumboJean-Luc Harousseau
Oct 7, 2005·International Journal of Hematology·Naoya OchiaiChihiro Shimazaki
Oct 10, 2006·Future Oncology·Jean-Luc Harousseau
Mar 6, 2008·Internal and Emergency Medicine·Francesca MagaliniPaolo Sansoni
Feb 28, 2007·Leukemia & Lymphoma·Morie A Gertz
May 3, 2008·Leukemia & Lymphoma·Morie A Gertz
May 28, 2013·Expert Opinion on Pharmacotherapy·Efstathios KastritisMeletios A Dimopoulos
Aug 28, 2012·Advances in Chronic Kidney Disease·Esftathios KastritisJoan Bladé
Aug 28, 2012·Advances in Chronic Kidney Disease·Frank Bridoux, Jean-Paul Fermand
Aug 28, 2012·Advances in Chronic Kidney Disease·Stephanie StringerPaul Cockwell
Apr 26, 2011·Néphrologie & thérapeutique·Eric MoumasFrank Bridoux
Sep 25, 2010·Cancer Treatment Reviews·Niels W C J van de DonkAntonio Palumbo
Dec 1, 2009·Critical Care Clinics·Dominique D Benoit, Eric A Hoste
Jun 6, 2009·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Hana KrakovicováKarel Ulbrich
Oct 13, 2007·Clinical Lymphoma & Myeloma·Sundar Jagannath
Aug 2, 2006·Clinical Lymphoma & Myeloma·Asher Chanan-Khan, Kena C Miller
Nov 13, 2007·Hematology/oncology Clinics of North America·Efstathios KastritisPaul G Richardson
Jun 15, 2007·La Revue de médecine interne·C Hulin
Jan 16, 2007·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Stuart M LichtmanMatti Aapro
Mar 21, 2007·The International Journal of Biochemistry & Cell Biology·Magda Melchert, Alan List
Jan 18, 2006·British Journal of Haematology·Alastair SmithUNKNOWN British Committee for Standards in Haematology
May 17, 2011·British Journal of Haematology·Jennifer M BirdUNKNOWN Haemato-oncology Task Force of British Committee for Standards in Haematology (BCSH) and UK Myeloma Forum
Sep 26, 2006·Best Practice & Research. Clinical Haematology·Amitabha Mazumder, Sundar Jagannath
Dec 14, 2005·Seminars in Hematology·Philip Greipp
Jan 12, 2012·Journal of Chemotherapy·V Kumar, S Chhibber
Jan 26, 2006·Expert Opinion on Pharmacotherapy·Ramón García-Sanz
Dec 3, 2014·Clinical Lymphoma, Myeloma & Leukemia·Norbert GrzaskoMarek Hus

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.